TheraRadar
← Back
Data updated: Jun 28, 2026

MCPRF

Pharma

MCPRF is a pharmaceutical company focused on Oncology, Neurology.

2012
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

MCPRF's Key Drugs

MCPRF's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MCPRF's Recent FDA Approvals

New NDA/BLA approvals for MCPRF over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MCPRF's Therapeutic Areas

MCPRF's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 67%
2 drugs
Neurology 33%
1 drugs

MCPRF's Top Competitors

MCPRF's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

MCPRF Pipeline Snapshot

Active clinical trials for MCPRF across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling